Hypochlorous acid responsive dimer prodrug, nanoparticle and preparation method and application thereof
The release of methylene blue and doxorubicin in tumor cells by activation and releasing hypochlorous acid-responsive dimer prodrugs is solved, and tumor-specific treatment and chemotherapy are achieved in the prior art Improvement of photodynamic synergy effect.
Patent Information
- Application Number
- CN202410690564.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-30
- Publication Date
- 2024-11-22
AI Technical Summary
The hydrophobicity of photosensitizers in the existing nano drug delivery system leads to insufficient release rate, resulting in poor photodynamic treatment effect and quenching effect. The drug loading and targeting of chemotherapy drugs and photosensitizers are insufficient, making it difficult to achieve tumors. Accurate treatment.
Hypochlorous acid-responsive dimer prodrug is used to connect methylene blue and doxorubicin through imidized bonds to form nanoparticles, and only activate and release photosensitizers and chemotherapeutic drugs in the hypochlorous acid environment to achieve tumor-specific treatment.
It improves the drug loading and targeting, reduces toxic side effects, enhances the tumor treatment effect, and achieves the synchronous effect of chemotherapy and photodynamic synergistic treatment.
Smart Images

Figure CN118994277A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medical technology, and specifically relates to a hypochlorous acid-responsive dimer prodrug, nanoparticles, and a preparation method and use thereof. Background Art
[0002] Chemotherapy is still one of the main means of clinical treatment of malignant tumors. However, the occurrence and development of cancer is a complex process of multi-factors, multi-stages, and multi-gene interactions. Therefore, the anti-tumor effect of relying on a single chemotherapy is limited, and it is very easy to induce tumor resistance. The sensitivity of patients with tumor resistance to chemotherapy drugs gradually decreases, which seriously affects the efficacy of chemotherapy and ultimately leads to cancer recurrence and metastasis. At the same time, traditional chemotherapy drugs have serious systemic toxic side effects, a low therapeutic index, and poor patient tolerance, which is also one of the reasons for the failure of chemotherapy in patients. Therefore, it is urgent to explore and develop safer and more efficient tumor precision combined treatment methods to improve the treatment effect of cancer, so as to maximize the quality of life of patients.
[0003] In recent years, the "diagnosis and treatment integrated" chemotherapy combined with photodynamic therapy strategy based on nanotechnology has shown great therapeutic advantages in the combined treatment of tumors. On the one hand, chemotherapy combined with photodynamic therapy can eliminate the heterogeneity of tumor cells and reduce the occurrence of tumor resistance. The singlet oxygen produced by photodynamic therapy can directly damage DNA and induce apoptosis of tumor cells without producing drug resistance; among them, singlet oxygen can also damage anti-apoptotic proteins (Bcl-2) and ATP-binding cassette transporters (ABCG2) involved in tumor resistance, thereby reducing the efflux of chemotherapy drugs and enhancing the therapeutic efficacy of chemotherapy drugs. On the other hand, photodynamic therapy can assist the implementation of chemotherapy and enhance the efficiency of tumor-targeted drug delivery. The singlet oxygen produced by photodynamic therapy can change the permeability of tumor blood vessels and tumor cell membranes, thereby enhancing the accumulation and spatial distribution of chemotherapy drugs in the tumor site; at the same time, the singlet oxygen produced during the treatment process can also destroy the lysosomal membrane of tumor cells, prompting chemotherapy drugs to quickly escape from lysosomes to the cytoplasm in order to better play an anti-tumor role, thereby realizing the organic combination of chemotherapy and photodynamic therapy and enhancing the anti-tumor efficacy. In addition, the "integrated diagnosis and treatment" guided by multimodal imaging technology helps to accurately guide tumor photodynamic therapy. Based on the above analysis, the "integrated diagnosis and treatment" chemotherapy-photodynamic therapy strategy is of great significance for the precise combined treatment of cancer.
[0004] In recent years, researchers have developed a series of strategies for the co-delivery of chemotherapy drugs and photosensitizers based on nanotechnology to achieve tumor chemotherapy combined with photodynamic therapy. Some studies have used physical encapsulation methods to simultaneously encapsulate photosensitizers and chemotherapy drugs in nanocarriers to achieve combined tumor therapy. However, non-covalent loading of drugs faces many problems such as low drug loading efficiency (<10%), poor stability, and easy drug leakage. It is difficult to achieve precise targeted controlled release of chemotherapy drugs and photosensitizers for tumors, and it still has significant toxic side effects on normal tissues. In response to this, other studies have used prodrug delivery strategies to chemically bond chemotherapy drugs and photosensitizers to polymer materials to achieve targeted co-delivery of chemotherapy drugs and photosensitizers. Although this system has improved the encapsulation efficiency of drugs to a certain extent, the drug loading is still low, and it is difficult to avoid the potential toxicity of the carrier material. In view of the above shortcomings, in order to increase the drug loading of drugs, some studies have adopted a small molecule prodrug self-assembly nanodrug delivery strategy to connect chemotherapy drugs and photosensitizers with enzyme-responsive peptides or redox-sensitive chemical bonds to form dimer prodrug conjugates. This type of dimer prodrug can self-assemble to form a nano co-delivery system with a high drug loading. Although the above drug delivery systems have a certain degree of tumor "integrated diagnosis and treatment" function, there are still many bottleneck problems: (1) They still use "always on" photosensitizers, which have low tumor-specific diagnostic capabilities and lack tumor selectivity. The photosensitizer fluorescence in the above delivery systems is in the "always on" state, which is easy to produce background signal interference and reduce tumor-specific imaging capabilities. In addition, due to the lack of tumor selectivity of the photosensitizer, it has potential phototoxicity; (2) The release rate of the hydrophobic photosensitizer is insufficient, resulting in poor photodynamic effect. Since the photosensitizers in the above nano drug delivery systems often have strong hydrophobicity, the release rate of the hydrophobic photosensitizer is insufficient during the release of chemotherapeutic drugs. (3) The photosensitizer has a quenching effect, which weakens the effect of photodynamic therapy. Hydrophobic photosensitizers are tightly wrapped in nanoparticles, which easily trigger the aggregation-induced quenching effect of photosensitizers; at the same time, the hydrophobic photosensitizers released by the nano-drug delivery system still have a tendency to aggregate in the cytoplasmic environment, and it is still difficult to get rid of the influence of the aggregation-induced quenching effect, thereby reducing the efficiency of photodynamic therapy and affecting the diagnosis and treatment of tumors. Doxorubicin (DOX) is a traditional chemotherapy drug, which is commonly used in the clinic to treat a variety of solid tumors such as breast cancer, gastric cancer, lung cancer, ovarian cancer, bladder cancer, lymphoma, and hematopoietic malignant tumors such as leukemia. DOX can induce severe cardiotoxicity, manifested as myocardial cell damage, apoptosis, necrotic cell death, and life-threatening left ventricular dysfunction, arrhythmia, and heart failure. DOX-induced cardiotoxicity is divided into acute, chronic, and delayed, with acute and chronic cardiotoxicity being the main ones. Acute cardiotoxicity often occurs during or within 2 to 3 days of administration, and is reversible through appropriate drug treatment. Chronic cardiotoxicity is progressive and irreversible, usually occurring about 1 year after medication.Currently, the exact mechanism of DOX-induced cardiotoxicity remains unclear. The more recognized mechanisms include oxidative stress, mitochondrial damage, DNA damage, calcium overload, cell autophagy and apoptosis.
[0005] Methylene blue (MB) is a hydrophilic, water-soluble phenothiazine photosensitizer with a wide light absorption range (600-900nm), an absorption peak at 660nm, and a singlet oxygen quantum yield of 0.52. In addition, MB, as a new type of photosensitizer with low dark toxicity, has been approved by the FDA for the treatment of human methemoglobinemia and has been widely used in photodynamic therapy to treat viruses, bacteria and cancer cells, and has shown great application prospects.
[0006] In 2019, Liang Junlong reported in "Preparation of Nanocarriers Based on Chemotherapy-Photothermal / Photodynamic Synergistic Therapy and Study on In Vitro Antitumor Performance" that MB and DOX were simultaneously encapsulated in BSA-coated PLGA microspheres by secondary emulsification-solvent evaporation to obtain the drug delivery system MB@DOX / PB. However, there is still a risk of leakage of the two drugs and toxic side effects on normal tissues after leakage; in addition, the fluorescence of MB in this drug delivery system is always on, resulting in a high background and a weakened tumor diagnosis ability.
[0007] Therefore, there is an urgent need to combine MB and DOX to develop a "trigger-activated" photosensitizer and chemotherapeutic drug co-delivery system to achieve the specific "activation" and rapid release of the chemotherapeutic drug DOX and the water-soluble photosensitizer MB in the local tumor, so that it can have specific tumor diagnosis capabilities while avoiding the quenching effect of the photosensitizer, reducing the systemic toxic side effects of the drug, and thereby enhancing the tumor diagnosis and treatment effect. Summary of the invention
[0008] In view of the shortcomings of the prior art described above, the purpose of the present invention is to provide a hypochlorous acid-responsive dimer prodrug, nanoparticles, and a preparation method and use thereof, so as to solve the problems existing in the prior art. The hypochlorous acid-responsive dimer prodrug and nanoparticles of the present invention have good biocompatibility, high drug loading rate, simple and controllable preparation process, easy-to-obtain raw materials, mild conditions, and have broad application prospects in the treatment of tumors with high hypochlorous acid concentrations.
[0009] To achieve the above objectives and other related objectives, the present invention is achieved through the following technical solutions.
[0010] One of the purposes of the present invention is to provide a hypochlorous acid-responsive dimer prodrug, the structural formula of which is shown below:
[0011]
[0012] When the hypochlorous acid-responsive dimer prodrug of the present application is not in contact with hypochlorous acid, the dimer prodrug is in a non-fluorescent state when it is not activated by hypochlorous acid; once activated by hypochlorous acid, fluorescent methylene blue and doxorubicin are released. At the same time, the hypochlorous acid-responsive dimer prodrug of the present application connects doxorubicin and subunit blue through an amide bond, effectively reducing the toxic and side effects of doxorubicin and subunit blue. In addition, the hypochlorous acid-responsive dimer prodrug of the present application can be selected and enriched in tumor cells, and is activated by hypochlorous acid to release methylene blue and doxorubicin. After light irradiation, methylene blue produces a photodynamic effect to treat tumors, and doxorubicin plays a chemotherapy treatment of tumors, achieving the effect of chemotherapy and photodynamic synergistic treatment of tumors.
[0013] The second object of the present invention is to provide a method for preparing the dimer prodrug as described above, comprising the following steps:
[0014] Doxorubicin and the compound shown in formula I are reacted in a solvent to obtain the dimer prodrug.
[0015]
[0016] In certain embodiments, the doxorubicin is selected from doxorubicin hydrochloride.
[0017] In certain embodiments, the mass ratio of doxorubicin to the compound represented by Formula I can be (0.2-2):1, (0.2-1.1):1, (0.8-1.5):1, (1.2-2):1, or 29:21.
[0018] In certain embodiments, the solvent is selected from one or more of dichloromethane, triethylamine and water.
[0019] In certain embodiments, the reaction temperature may be 10-30°C, 10-16°C, 12-25°C, or 22-30°C.
[0020] In certain embodiments, the reaction time is 10 to 60 hours, or 10 to 35 hours, or 28 to 46 hours, or 42 to 60 hours, or 48 hours.
[0021] In certain embodiments, the reaction is carried out in a protective atmosphere. The protective atmosphere is selected from nitrogen.
[0022] In certain embodiments, the reaction further includes post-treatment, wherein the post-treatment includes one or more of extraction, washing and drying;
[0023] In certain specific embodiments, dichloromethane is used for extraction.
[0024] In certain specific embodiments, washing is performed with an aqueous sodium chloride solution.
[0025] In certain specific embodiments, the drying is carried out using anhydrous sodium sulfate.
[0026] In some specific embodiments, separation and purification are also included. The separation and purification uses a volume ratio of dichloromethane to ethanol of 80:1 for gradient elution, followed by rotary evaporation.
[0027] In certain specific embodiments, the compound of formula I is dissolved in dichloromethane and triethylamine to obtain a solution of the compound of formula I, doxorubicin is dissolved in water to obtain an aqueous solution of doxorubicin, and then the aqueous solution of doxorubicin is added dropwise to the solution of the compound of formula I to react and obtain the dimer prodrug.
[0028] The third object of the present invention is to provide a nanoparticle comprising the dimer prodrug as described above and a polymer material.
[0029] The present application co-assembles a dimer prodrug and a polymer material into nanoparticles MD with uniform morphology and particle size. After being administered to tumor cells, the high concentration of hypochlorous acid in the tumor cells can specifically activate the nanoparticles and simultaneously release the chemotherapy drugs DOX and MB. Under the irradiation of near-infrared light, MB can mediate the photodynamic effect and enhance the killing ability of tumor cells by generating a large amount of ROS in combination with the chemotherapy drug DOX. The nanoparticles of the present application have low toxicity to cells and can target and select tumor cells to release and kill tumor cells, effectively improving the survival cycle.
[0030] In certain embodiments, the polymer material is a polymer material comprising any one or more block structures of polyethylene glycol, polylactic acid, polyglycolide, poly(lactide-co-glycolide), polycaprolactone, polytrimethylene carbonate, polydioxanone, polyacrylic acid, polyacrylate and polypolypeptide.
[0031] In some specific embodiments, the polymer material is one or more of polyethylene glycol-polylactic acid, polyethylene glycol-polyglycolide, polyethylene glycol-poly(lactide-glycolide), polyethylene glycol-polycaprolactone, polyethylene glycol-polytrimethylene carbonate and polyethylene glycol-polydioxanone.
[0032] In some more specific embodiments, the polymer material is polyethylene glycol-polycaprolactone (DSPE-PEG). Preferably, the molecular weight of the polyethylene glycol (PEG) is 2000.
[0033] In certain embodiments, the encapsulation efficiency of the nanoparticles is 80-95%, or 90.85%, 84.82% and 88.41%.
[0034] In certain embodiments, the particle size of the nanoparticles may be 80-120 nm, or may be 100 nm.
[0035] A fourth object of the present invention is to provide a method for preparing the nanoparticles as described above, comprising the following steps:
[0036] The dimer prodrug and the polymer material are dissolved in an organic solvent to obtain a mixed solution, and the mixed solution is added dropwise into an inorganic solvent to obtain the nanoparticles.
[0037] In certain embodiments, the organic solvent is selected from one or both of ethanol and dimethyl sulfoxide (DMSO).
[0038] In certain embodiments, the inorganic solvent is a buffer or water.
[0039] In some embodiments, the dimer prodrug is dissolved in an inorganic solvent, the polymer material is dissolved in an organic solvent, and the mixture is mixed to obtain the mixed solution. Specifically, the dimer prodrug is dissolved in DMSO, the polymer material is dissolved in DMSO, and then mixed, and the mixed solution is added dropwise to PBS, and the solid-liquid separation is performed to obtain the nanoparticles.
[0040] A fifth object of the present invention is to provide a pharmaceutical composition comprising the dimer prodrug as described above or the nanoparticles as described above, and a pharmaceutically acceptable excipient.
[0041] In the pharmaceutical composition described in the present application, the pharmaceutically acceptable excipient should be compatible with the composite material, that is, it can be blended with it without significantly reducing the effect of the composite material under normal circumstances. In the pharmaceutical composition described in the present application, the pharmaceutically acceptable excipient is selected from one or more of a carrier, a diluent, a binder, a lubricant and a wetting agent. Specific examples of some substances that can be used as pharmaceutically acceptable carriers, diluents, binders, lubricants and wetting agents are sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium methylcellulose, ethylcellulose and methylcellulose; tragacanth powder; malt; gelatin; talc; solid lubricants, such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cocoa butter; polyols, such as propylene glycol, glycerol, sorbitol, mannitol and polyethylene glycol; alginic acid; emulsifiers, such as Tween; wetting agents, such as sodium lauryl sulfate; colorants; flavorings; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffer, etc. These substances are used as needed to help the stability of the formulation or to help improve the activity or its biological effectiveness.
[0042] The sixth object of the present invention is to provide the use of the dimer prodrug as described above, the nanoparticle as described above, or the pharmaceutical composition as described above in the preparation of anti-tumor drugs.
[0043] In certain embodiments, the anti-tumor drug is administered by injection, orally, or topically.
[0044] In certain embodiments, the tumor in the anti-tumor drug is selected from one or more of breast cancer, bronchial lung cancer, ovarian cancer, soft tissue sarcoma, osteogenic sarcoma, rhabdomyosarcoma, Ewing sarcoma, blastoma, neuroblastoma, bladder cancer, thyroid cancer, prostate cancer, head and neck squamous cell carcinoma, testicular cancer, gastric cancer and liver cancer. Preferably, it is breast cancer.
[0045] In certain embodiments, the anti-tumor drug is a photodynamic and chemotherapy combined therapy drug.
[0046] In certain embodiments, the dosage of the anti-tumor drug is: in terms of nanoparticles, for mice, intravenous administration is used, once a day, and each dose is 5 mg / kg to 20 mg / kg. The nanoparticle administration in this application is generally a course of 10 to 14 days.
[0047] The present invention further provides a method for treating tumors, which comprises administering an effective amount of the nanoparticles as described above or the pharmaceutical composition as described above to a subject in need. The method may also be in vitro or non-therapeutic, and the subject is a mammal, such as but not limited to humans, primates, livestock, pets, laboratory test animals, or captured wild animals. The subject is preferably a primate. The subject is most preferably a human. The subject may be a patient with a tumor or an individual who expects to prevent a tumor. The nanoparticles or pharmaceutical composition may be administered to the subject before, during, or after receiving tumor treatment.
[0048] Once activated by hypochlorous acid (HClO), the hypochlorous acid-responsive dimer prodrug and nanoparticles of the present application will release the corresponding DOX and MB with anti-inflammatory properties that can produce bright fluorescence, and can cooperate with chemical-photodynamic therapy to treat tumors.
[0049] Compared with the prior art, the present invention has the following beneficial effects:
[0050] 1) The dimer prodrug of the present application is formed by connecting methylene blue and doxorubicin through an amide bond. The dimer prodrug is in a non-fluorescent state when not stimulated by hypochlorous acid. Once activated by HClO stimulation, it quickly releases fluorescent MB and doxorubicin; the dimer prodrug of the present application effectively reduces the toxic and side effects of administering methylene blue and doxorubicin alone, and the preparation raw materials are cheap and easily available, the preparation process is simple, the preparation conditions are mild, and it is easy to industrialize production.
[0051] 2) The nanoparticles prepared by the present invention have a small particle size, a rounded and uniform spherical shape, an encapsulation rate of 80-95%, and the particle size is almost unchanged in PBS, with good stability.
[0052] 3) The dimer prodrug and nanoparticles of the present application can be selectively enriched in tumor cells without being deposited in the heart, spleen, lungs and kidneys; they can synchronously and rapidly release the chemotherapy drug DOX and the photosensitizer MB in a hypochlorous acid environment, greatly reducing the off-target rate of the drug and reducing the toxic side effects of the drug.
[0053] 4) The nanoparticles of the present invention are modified with polymer materials, especially PEGylation, which increases the blood circulation time of the nanoparticles in the body, improves the plasma half-life, and increases the accumulation ability of the drug at the tumor site.
[0054] 5) The nanoparticles of the present invention are loaded with photosensitizer MB and chemotherapy drug DOX at the same time, which can realize tumor chemotherapy combined with photodynamic therapy, effectively inhibit tumors, and prolong the survival period.
[0055] 6) The nanoparticles prepared by the present invention have good biocompatibility and degradability, and the raw materials are cheap and easily available, the preparation process is simple, and the preparation conditions are mild. It is an excellent anticancer drug targeting nanocarrier. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 Shown is a schematic diagram of the synthesis route of the dimer prodrug MB-DOX in Example 1 of the present invention.
[0057] Figure 2 Shown is the hydrogen nuclear magnetic resonance spectrum of the dimer prodrug MB-DOX in Example 1 of the present invention.
[0058] Figure 3 Shown is the carbon nuclear magnetic resonance spectrum of the dimer prodrug MB-DOX in Example 1 of the present invention.
[0059] Figure 4 Shown is the mass spectrum of the dimer prodrug MB-DOX in Example 1 of the present invention.
[0060] Figure 5 This is a transmission electron microscope photograph of nanoparticles MD in Example 2 of the present invention.
[0061] Figure 6 Shown is the standard curve of MB-DOX in Example 2 of the present invention.
[0062] Figure 7The graphs show the in vitro hypochlorous acid responsiveness and active oxygen release test of the nanoparticles MD in Example 2 of the present invention; wherein A is the ultraviolet absorption spectrum of HClO and MD at different concentrations, and B is the active oxygen release of MD.
[0063] Figure 8 It shows the selectivity of nanoparticles MD in Example 3 of the present invention to different ions.
[0064] Fig. 9 Shown are the results of HClO responsiveness of nanoparticles MD in Example 3 of the present invention in NIH3T3 and 4T1 cells, wherein A represents NIH3T3 cells; B represents 4T1 cells.
[0065] Fig.10 It shows the effect of light-treated nanoparticles MD in Example 4 of the present invention on the activity of NIH3T3 and 4T1 cells.
[0066] Fig.11 The graph shows the in vivo fluorescence imaging and biodistribution results after the nanoparticles MD in Example 5 of the present invention were administered to mice.
[0067] Fig.12 The figures show the anti-tumor effects of different groups of mice in Example 5 of the present invention; A is the tumor weight of mice, B is the volume of mice; and C is the survival rate of mice. DETAILED DESCRIPTION
[0068] The following is a description of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0069] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are intended to describe specific embodiments, rather than to limit the scope of protection of the present invention. The test methods in the following examples without specifying specific conditions are generally carried out under conventional conditions or under conditions recommended by the manufacturers.
[0070] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the grasp of the prior art by those skilled in the art and the record of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention can also be used to realize the present invention.
[0071] In order to further illustrate the above-mentioned synthesis method of the present application and the technical effects achieved therein, the following examples are used for further explanation and illustration.
[0072] All raw materials in this application have no special restrictions on their sources and can be obtained through commercial channels.
[0073] In the following embodiments of the present application, MB represents methylene blue, DOX represents doxorubicin, MB-DOX represents hypochlorous acid-responsive dimer prodrug, MD represents nanoparticles formed by hypochlorous acid-responsive dimer prodrug, and HClO represents hypochlorous acid.
[0074] Example 1 Preparation of hypochlorous acid responsive dimer prodrug (MB-DOX)
[0075] like Figure 1 As shown, this embodiment 1 provides a method for preparing a hypochlorous acid-responsive dimer prodrug (MB-DOX), comprising the following steps:
[0076] 1.1 Synthesis of FDOCl
[0077] 1) Weigh 5 g of methylene blue (15.63 mmol, 1.0 eq) and dissolve it in 50 mL of ultrapure water, add 25 mL of dichloromethane and 6.63 g of Na2CO3 (62.52 mmol, 4.0 eq), stir well at 40°C under nitrogen protection to obtain a mixed solution A.
[0078] 2) Weigh 10.89 g of sodium dithionite (62.52 mmol, 4 eq) and dissolve it in 70 mL of ultrapure water. Then add the solution into the mixed solution A in 1) with a syringe, and stir it at 40° C. under nitrogen protection for 15-30 min until the solution turns yellow to obtain a mixed solution B.
[0079] 3) Subsequently, the mixed solution B in 2) was placed in an ice water bath. After the mixture was completely cooled, 20 mL of a dichloromethane solution containing 2.78 g of bis(trichloromethyl) carbonate (BTC) (9.38 mmol, 0.6 eq) was slowly added dropwise, and the reaction was continued by stirring for 1 h.
[0080] 4) The reaction solution obtained in 3) was poured into 200 mL of ice water and stirred for 15 min. The final product was extracted with dichloromethane solution for three times. The extracts were combined, washed with sodium chloride brine, dried over anhydrous sodium sulfate, and dried with a rotary evaporator. The dried product was separated and purified with a liquid phase (ethyl acetate / n-hexane = 1 / 10) to obtain a white product FDOCl-2.
[0081] 1.2 Synthesis of MB-DOX
[0082] 1) Weigh 29 mg of FDOCl-2 (29 mg, 0.05 mmol) obtained in step 1.1 and dissolve it in 3 mL of DCM (dichloromethane), add 46 μL of TEA (triethylamine) solution (0.34 mmol), and stir for 15 min under nitrogen protection to obtain a FDOCl-2 solution.
[0083] 2) The FDOCl-2 solution obtained in 1) is then placed in an ice water bath. After it is completely cooled, 21 mg of doxorubicin hydrochloride is weighed and dissolved in 2 mL of pure water to obtain a doxorubicin solution. The doxorubicin solution is then slowly added dropwise to the cooled FDOCl-2 solution and stirred at room temperature for 48 hours to obtain a reaction product.
[0084] 3) The reaction product was extracted with a dichloromethane solution for three times, 10 mL each time. The extracts were combined, washed with sodium chloride brine, dried over anhydrous sodium sulfate, concentrated using a rotary evaporator, and separated and purified using a silica gel column (the volume ratio of dichloromethane to ethanol was 80:1 for gradient elution, i.e., DCM:EtOH=80:1), and then dried using a rotary evaporator to obtain the final product, the dimer prodrug MB-DOX.
[0085] Mass spectrometry and nuclear magnetic resonance spectroscopy were used to determine the structure of the MB-DOX prodrug in Example 1. Figure 2 , 3 The mass spectrometry results are shown in Figure 4 .
[0086] The results of spectrum analysis are as follows:
[0087] 1 H NMR(400MHz,Chloroform-d)δ13.91(s,1H),13.19(s,1H),8.00(d,J=7.6Hz,1H),7.75(t,J=8.1Hz,1H),7.36 (d,J=8.4Hz,1H),7.29–7.22(m,3H),6.60(d,J=2.1Hz,2H),6.57–6.50(m,2H),5.49–5.43(m,1H),5.30(d,J=8 .0Hz,1H),5.23(s,1H),4.73(s,2H),4.58(s,1H),4.11(q,J=6.2Hz,1H),4.05(s,4H),3.71(s,1H),3.21(d,J =18.8Hz,1H),3.07–2.99(m,1H),2.87(s,12H),2.31(d,J=14.9Hz,1H),2.21–2.07(m,2H),1.90–1.64(m,5H).
[0088] 13 C NMR (101MHz, CDCl3) δ213.05,185.98,185.54,159.98,155.21,154.62,154.35,147.88,13 4.69,134.45,132.91,132.74,132.63,127.07,125.98,119.81,118.79,117.42,110.48,1 10.29,110.20,109.84,99.94,75.49,68.60,68.58,66.42,64.54,55.64,46.03,39.61,34.71,32.90,30.90,30.61,29.29,29.11,28.67,28.63,28.34,28.26,21.67,15.86,13.10.
[0089] Mass spectrum HRMS (ESI) m / z for C 44 H 46 N4NaO 12 S + [M+Na] + 877.2725; found 877.2727
[0090] Example 2 Preparation method of nanoparticles MD
[0091] In this Example 2, the dimer prodrug of Example 1 is subjected to nanoprecipitation to obtain nanoparticles (MD), which include the following:
[0092] 2.1 Preparation of MD nanoparticles
[0093] 80 μL of MB-DOX DMSO solution (10 mg / mL, 80 wt%) and 20 μL of DSPE-PEG2k DMSO solution (10 mg / mL, 20 wt%) were mixed thoroughly.
[0094] Under vigorous stirring (1000 rpm), the above solution was quickly added dropwise to 1.5 mL of PBS and stirred at room temperature for 0.5 h. The organic solvent DMSO and unencapsulated dimer prodrug MB-DOX were removed by centrifugation using an ultrafiltration tube to obtain nanoparticles MD.
[0095] The morphology of the nanoparticles MD obtained in step 2.1 was characterized by TEM. Figure 5 Middle A.
[0096] from Figure 5 As shown in Figure A, the nanoparticles MD are spherical, well dispersed, and have no aggregation.
[0097] 2.2 Morphology, particle size and surface potential of MD nanoparticles
[0098] The nanoparticles MD obtained in step 2.1 were placed in 10% FBS, 25 μM HClO was added to the MD nanoparticle solution, and the particle size was immediately detected by DLS (dynamic light scattering). The detection results are shown in Figure 5 Middle B.
[0099] Meanwhile, nanoparticles MD were used as a control.
[0100] from Figure 5 From Figure B, we can see that the particle size distribution of MD is about 100nm; the particle size distribution of MD in FBS is slightly lower than 100nm; and after adding HClO to MD, the particle size changes greatly, the particle size becomes significantly smaller and a new peak appears, indicating that MD is degraded in the hypochlorous acid environment, resulting in changes in the MD particle size.
[0101] The particle size and potential results of nanoparticles MD are shown in Table 2.
[0102] 2.3 Study on the hypochlorous acid response performance of nanoparticles
[0103] Nanoparticles MD and HClO were mixed in vitro for hypochlorous acid responsiveness experiments. Based on the total volume of the mixture, the concentration of nanoparticles was 20 μM, and the concentration of hypochlorous acid was 0, 5, 10, 25, 50, 100, 200, and 400 μM, respectively. Then, the mixture was continuously tested under UV spectrophotometry. The results are shown in Figure 7 Middle A.
[0104] Figure 7 A in the figure is the ultraviolet absorption spectrum of nanoparticles MD and hypochlorous acid of different concentrations. In the figure, from top to bottom are the ultraviolet absorption spectrum curves of hypochlorous acid with concentrations of 0, 5, 10, 25, 50, 100, 200, and 400 μM.
[0105] from Figure 7 As shown in Figure A, compared with 0 μM hypochlorous acid, MB-DOX exhibited a 300-fold increase in absorbance at 664 nm, and the absorbance gradually increased with the increase in the concentration of hypochlorous acid.
[0106] 2.4 Study on the photodynamic properties of nanoparticles
[0107] Photosensitizer MB can sensitize oxygen to produce singlet oxygen under laser irradiation. Singlet oxygen is a reactive oxygen species that can induce cell apoptosis and necrosis and is commonly used in photodynamic therapy of tumors. This example uses SOSG fluorescence decay method to measure the generation of singlet oxygen in the system.
[0108] Singlet oxygen green fluorescent probe (SOSG) is an indicator of singlet oxygen, which has strong absorption at 450nm. When it reacts with singlet oxygen in the system, the ability of the system to produce singlet oxygen can be judged according to the degree of decrease in absorbance at 450nm. Singlet oxygen green fluorescent probe (SOSG) is used to detect the singlet state of MD ( 1 O2) release ability probe.
[0109] Divided into 4 groups, including:
[0110] The SOSGonly group represented SOSG only, without adding MD and HClO.
[0111] The SOSG+HClO group represents a mixture of SOSG and HClO, and the concentration of SOSG in the mixture is 10 μM.
[0112] The MD+SOSG group represents a mixture formed by SOSG and MD, in which the concentration of SOSG is 10 μM and the concentration of MD is 10 μM.
[0113] The MD+SOSG+HClO group represents a mixture of SOSG, MD and HClO, in which the concentration of SOSG is 10 μM and the concentration of MD is 10 μM.
[0114] The mixed solution of each group was heated at 660nm with 0.5W·cm -2 The mixed solution was irradiated with a light power density of 100 nm for 2 minutes, and then single laser irradiation was performed, and the absorbance change was immediately measured at 450 nm using a microplate reader.
[0115] Figure 7 Middle B is the active oxygen release graph of nanoparticles MD in different groups.
[0116] from Figure 7 As shown in Figure B, after incubation with MD and HClO, 1 The production of O2 causes the absorption of SOSG at 450nm to increase continuously with the extension of illumination time, that is, the extension of illumination time can produce more singlet oxygen and restore the ability of MB to produce reactive oxygen.
[0117] 2.5. Investigation of encapsulation efficiency
[0118] Weigh 1 mg MB-DOX and dissolve it in 1 mL DMSO solution to obtain a mother solution, then use DMSO to dilute the mother solution to 200 μg / mL, 100 μg / mL, 50 μg / mL, and 10 μg / mL, and continuously detect under 450-700 nm UV spectrophotometry. The results are shown in Figure 7 Middle A.
[0119] from Figure 7As shown in Figure A, the maximum absorption peak of MB-DOX in DMSO is 484 nm.
[0120] Then, based on the determined maximum absorption peak, the absorbance at each concentration gradient was measured, and then a standard curve was drawn based on the concentration and absorbance.
[0121] Sample 1 is: 0.13 mg MB-DOX is dissolved in 200 μL of DMSO solution, and then fully mixed with 20 μL of DMSO solution of DSPE-PEG2k (10 mg / mL, 20 wt%), and the remaining operations are the same as those in Example 2.1, to obtain 1.5 mL of sample 1.
[0122] Sample 2 is: 0.13 mg MB-DOX is dissolved in 200 μL of DMSO solution, and then fully mixed with 20 μL of DSPE-PEG2k DMSO solution (10 mg / mL, 20 wt%), and the remaining operations are the same as Example 2.1, to obtain 1.5 mL of sample 1.
[0123] Sample 3 was prepared by dissolving 0.13 mg MB-DOX in 200 μL DMSO solution, and then mixing the mixture with 20 μL DMSO solution of DSPE-PEG2k (10 mg / mL, 20 wt%). The remaining operations were the same as those in Example 2.1, and 1.2 mL of sample 1 was obtained.
[0124] The drug concentration of MB-DOX was calculated based on the standard curve, and the drug mass m of MB-DOX was calculated from the concentration. 实 =cVM; the encapsulation efficiency of nanoparticles MD was obtained.
[0125] The calculation formula is as follows: Encapsulation efficiency (EE) = m 实 / m 理 , m 理 Represents the initial dosage of the drug
[0126] Table 2
[0127] sample 1 2 3 Volume (mL) 1.5 1.5 1.2 Absorbance 0.9754 0.9176 1.1637 Initial feed amount (mg) 0.13 0.13 0.13 Encapsulation rate (%) 90.85 84.82 88.41
[0128] Example 3 HClO selectivity of nanoparticles MD in vitro
[0129] In this Example 3, the nanoparticles MD obtained in step 2.1 of Example 2 were used to treat tumor cells to study the selectivity of the nanoparticles MD to tumor cells and to different ions. The process includes the following:
[0130] 3.1. Selectivity for different ions
[0131] MB-DOX was dissolved in DMSO to obtain a 5 μM MB-DOX solution, and then the following solution was added with a final concentration of 20 μM, incubated at room temperature in the dark for 1 hour, and the fluorescence spectrum was recorded. The fluorescence spectra were detected by a fluorescence photometer to observe whether there was a MB fluorescence absorption peak at an excitation wavelength of 660 nm and an emission wavelength between 680 and 830 nm.
[0132] Blank: distilled water.
[0133] Obtaining of hypochlorous acid (HClO): 14.5 wt % sodium hypochlorite (NaClO) solution.
[0134] Reactive oxygen species ( 1 O2) acquisition: 1 mL of 3 wt% hydrogen peroxide (H2O2) solution was added to 9 mL of ice water, and 0.5 mL of 5 wt% sodium hypochlorite solution was slowly added dropwise.
[0135] Superoxide anion (O2 2- ) was obtained by dissolving 1 g of potassium dimethyl sulfoxide (Na2O2) in 50 mL of ice water and stirring slowly to generate superoxide anions (O2 2- ).
[0136] Obtaining hydroxyl radicals (·OH): 10 mL of 0.1 M ferrous sulfate (FeSO4) solution was added to 50 mL of ice water, stirred, and 5 mL of 30 wt% aqueous solution of hydrogen peroxide (H2O2) was slowly added dropwise.
[0137] Peroxynitrite (ONOO - ) is obtained by dissolving 5 mL of 30 wt% hydrogen peroxide (H2O2) in 50 mL of distilled water to obtain an aqueous hydrogen peroxide solution, and preparing 15 mL of an aqueous 0.3 M sodium nitrite solution in advance. In an ice bath, the aqueous hydrogen peroxide solution is added dropwise to the aqueous sodium nitrite solution while stirring. A pH meter is used to monitor the pH value of the solution to ensure that the pH value is between 6.5 and 7.5, and 0.5 M sodium carbonate is used to adjust the pH value.
[0138] Figure 8 This is the selectivity result diagram of nanoparticle MD for different ions.
[0139] from Figure 8 It can be seen that nanoparticles MD have the highest selectivity for HClO and are not affected by other reactive oxygen species such as 1 O2, HClO, H2O2, ONOO - , OH and O2 2- Only hypochlorous acid can increase the fluorescence value of MD at 660nm by more than 4 times, indicating that MD is specific for HClO.
[0140] 3.2. Targeting selectivity for tumor cells
[0141] 1) Mouse embryonic fibroblasts (NIH3T3) and mouse breast cancer cells (4T1) were cultured at 4×10 4 The cells were seeded at a density of 10 cells / mL in a 24-well microplate in 2 mL of culture medium containing 10% fetal bovine serum.
[0142] 2) After the cells attached for 12 hours, the plate was washed with 100 μL / well PBS. The cells were then cultured in a medium containing MD (20 μM) for 3 hours, washed twice with PBS, collected with trypsin, and then diluted with 200 μL PBS. The cells were then resuspended and the DOX fluorescence signal and MB fluorescence signal (MB: PC5.5; DOX: PE) were collected by flow cytometry (FC).
[0143] At the same time, a PBS control group was set up, in which the culture medium containing PBS was used instead of the culture medium containing MD.
[0144] Fig. 9 The results of the selectivity of mouse embryonic fibroblasts (NIH3T3) and mouse breast cancer cells (4T1) to HClO when treated with nanoparticles MD. The left column in each figure is the PBS group, and the right column is the MD administration group. For example, taking NIH3T3 cells as an example, the left side of the DOX flow cytometric graph is the value of the PBS group, and the right side is the value of the nanoparticle MD group.
[0145] from Fig. 9 It can be seen that compared with the PBS group, when the nanoparticles MD treated NIH3T3 cells and 4T1 cells, the fluorescence signal of DOX increased by 37.92% and 22.13%, respectively, indicating that NIH3T3 cells can take up more nanoparticles. In the medium containing MD, the fluorescence signal of MB successfully activated in 4T1 cells was 78.8%, which was 6.91 times that of NIH3T3 cells, indicating that 4T1 cells can activate more nanoparticles.
[0146] It shows that the nanoparticles MD of the present application can specifically select tumor cells.
[0147] Example 4 Cytotoxicity study of nanoparticles MD
[0148] In this Example 4, the cytotoxicity of the drug to mouse embryonic fibroblasts (NIH3T3) and mouse breast cancer cells (4T1) was studied. The following are included:
[0149] The patients were divided into 5 groups, namely MD group, MD+, MB+, DOX and MB+and DOX group, specifically:
[0150] MD group: only given nanoparticles MD without light irradiation;
[0151] MD+ group: after administration of assembled nanoparticles MD, light irradiation was given;
[0152] MB+ group: methylene blue was given followed by light irradiation;
[0153] DOX group: only given doxorubicin DOX;
[0154] MB+and DOX group: a mixture of MB and DOX was administered, followed by light irradiation. The preparation method of the mixture of MB and DOX was as follows: MB and DOX were dissolved in PBS, respectively, and then mixed at a volume ratio of 1:1. Specifically, 2μM MB+and DOX refers to a mixture of 2μm MB solution and 2μm DOX solution at a volume ratio of 1:1; 5μM MB+and DOX refers to a mixture of 5μm MB solution and 5μm DOX solution at a volume ratio of 1:1; 8μM MB+and DOX refers to a mixture of 8μm MB solution and 8μm DOX solution at a volume ratio of 1:1; 10μM MB+and DOX refers to a mixture of 10μm MB solution and 10μm DOX solution at a volume ratio of 1:1; 20μM MB+and DOX refers to a mixture of 20μm MB solution and 20μm DOX solution at a volume ratio of 1:1.
[0155] 1) Mouse embryonic fibroblasts (NIH3T3) and mouse breast cancer cells (4T1) were cultured at 1×10 4 The cells were seeded in a 96-well plate at a density of 10 cells / well and then cultured at 37°C in 5% carbon dioxide for 24 hours.
[0156] 2) Then the cells were incubated with different groups of drugs at different concentrations (0, 2, 5, 8, 10, 20 μM) for 24 h, the drug solution was aspirated, and the cells were washed twice with 200 μL / well PBS. Each well of the MD+ group, MB+ group, and MB+and DOX group was illuminated with 400 mW·cm -2 The cells were irradiated for 2 min, and the other two groups were not irradiated. Then, 100 μL RPMI1640 containing 10% CCK-8 was added to each 96-well plate and cultured at 37°C for 2 h, with five parallel groups.
[0157] 3) The absorbance at 450 nm was measured using an ELISA reader (Bio Tek Instruments Co., Ltd.), and the cell viability was calculated based on the absorbance.
[0158] Fig.10 The effects of different treatment groups on the activity of NIH3T3 and 4T1 cells. A is NIH3T3 cells; B is 4T1 cells.
[0159] from Fig.10It can be seen that the MD group and the MD+ group did not show obvious cytotoxicity to embryonic fibroblasts, and even at a high concentration of 20μM, there was no toxicity problem caused by the drug. However, the MB+ group and the DOX group showed obvious cytotoxicity at only 2μM. The MD group can significantly kill breast cancer cells after light irradiation.
[0160] After light treatment with 20μM concentration of nanoparticle MD in the MD+ group, the survival rate of embryonic fibroblasts was about 78.0784%, indicating that nanoparticle MD has high safety and low toxicity to normal embryonic fibroblasts; and after light treatment with 20μM concentration of nanoparticle MD, the survival rate of breast cancer cells dropped to 10.2877703%, indicating that MD has a strong killing effect on cancer cells.
[0161] In the DOX group, when the drug concentration was 20 μM, the survival rate of embryonic fibroblasts was only about 6.125%, and the survival rate of breast cancer cells was 13.616398%, indicating that DOX was highly toxic to normal cells.
[0162] In the MB+ group, when the drug concentration was 20 μM, the survival rate of embryonic fibroblasts was only about 6.2886%, and the survival rate of breast cancer cells was 15.0470553%, indicating that MB was also highly toxic to normal cells.
[0163] In the MB+and DOX group, when the drug concentration was 20 μM, the survival rate of embryonic fibroblasts was only about 1.215%, and the survival rate of breast cancer cells was 7.246%, indicating that MB and DOX were also highly toxic to normal cells after direct mixing. In summary, the present application forms a dimer prodrug by connecting MB and DOX with FDOCl-2, which has a significant killing effect on cancer cells while significantly reducing the toxicity of MB and DOX used alone.
[0164] Example 5 In vivo study of nanoparticle MD
[0165] In this Example 5, the biodistribution and anti-tumor effect of nanoparticles MD in mice were investigated, including the following:
[0166] 5.1 Biodistribution of MD nanoparticles in mouse tumor models
[0167] 1) Balb / c mice were inoculated with 1×10 6 4T1 mouse breast cancer cells were used to establish an orthotopic 4T1 breast cancer mouse model.
[0168] 2) When the tumor volume reaches 300mm 3At the same time, 4T1 tumor-bearing mice were intravenously injected with MD drug (10 mg / kg) and observed using a live animal imager (excitation wavelength: 660 nm, emission wavelength: 700 nm) at 1 h, 2 h, 4 h, 8 h, and 12 h after injection.
[0169] 3) 12 h after injection, mice were killed, and tumors and major organs (heart, liver, spleen, lung, and kidney) were collected and analyzed using a small animal in vivo imaging system ( LuminaⅢII, PerkinElmer, USA) was used for in vitro imaging to observe the distribution of nanoparticles in vivo.
[0170] At the same time, with MB as the control group, the mouse model was constructed in the same manner as above, and the concentration of the injected MB drug was 10 mg / kg.
[0171] Fig.11 Fluorescence imaging and biodistribution in different groups of mice. A is the in vitro imaging result after 1h, 2h, 4h, 8h, and 12h of injection, and B is the imaging of tumors and major organs in the MD group, from left to right, tumor, heart, liver, spleen, lung, and kidney. The red dotted line in Figure A represents the tumor site.
[0172] from Fig.11 As shown in Figure A, 4 hours after injection, the fluorescence of the MB group diffused throughout the body; while the MD group only accumulated at the tumor site and effectively activated the MB fluorescence, indicating that the nanoparticle MD has a good tumor enrichment ability.
[0173] from Figure 1 As shown in Figure B, in the MB group, fluorescence was present in the heart, liver, spleen, lung, and kidney; while in the MD group, fluorescence was mainly present in the tumor tissue, and there was no fluorescence in the heart, spleen, lung, and kidney. The reason for the fluorescence in the liver was that the liver was the organ for MD metabolism. This comprehensively indicates that the MD of the present application has tumor targeting and does not accumulate in other tissues.
[0174] 5.2 Evaluation of the anti-tumor efficacy of MD in vivo
[0175] 1) Balb / c mice were inoculated with 1×106 4 T1 mouse breast cancer cells, 4T1 tumor-bearing mouse model was established; when the tumor volume reached 100mm 3 At about 1:10 pm, 4T1 tumor-bearing mice were randomly divided into 4 groups (n=5 in each group), and the groups were as follows:
[0176] PBS+ group: Mice were intravenously injected with PBS buffer. 8 h after injection, the mice were anesthetized with isoflurane and irradiated with NIR laser (660 nm, 0.5 W / cm 2, 2min), the drug was administered every other day, and the day of feeding was recorded as D1, that is, on D1, D3, D5, D7, D9, D11, D13, and D15, the same below.
[0177] MB+ group: Mice were intravenously injected with 10 mg / kg of methylene blue in PBS. 8 h after injection, the mice were anesthetized with isoflurane and irradiated with NIR laser (660 nm, 0.5 W / cm 2 , 2min), administered every other day.
[0178] DOX group: Mice were intravenously injected with 10 mg / kg of doxorubicin DOX in PBS. 8 h after injection, the mice were anesthetized with isoflurane and the tumor site was irradiated with NIR laser (660 nm, 0.5 W / cm 2 , 2min), administered every other day.
[0179] MD+ group: mice were intravenously injected with 10 mg / kg of MD nanoparticles in PBS. 8 h after injection, the mice were anesthetized with isoflurane and irradiated with NIR laser (660 nm, 0.5 W / cm 2 , 2min), administered every other day.
[0180] On the day of drug administration, the length and width of the tumor in each group were measured and the tumor volume (mm 3 ) is V = (a × b 2 ) / 2, where a and b are the length and width of the tumor, respectively. When the mouse died or the tumor volume reached 1000mm 3 The mice were considered dead when .
[0181] The tumor volume results of each group are shown in Fig.12 Middle B.
[0182] from Fig.12 As shown in Figure B, the tumor growth rate of mice in the MD+ group was much lower than that in the PBS+ group, showing a significant difference.
[0183] After 15 days of the experiment, the tumors were taken and weighed. Fig.11 Middle A.
[0184] from Fig.12 As shown in Figure A, the tumor weight of mice in the MD+ group was 1.90 g lower than that in the PBS+ group.
[0185] The survival rate of each group of mice was counted. Fig.12 Middle C.
[0186] from Fig.12As shown in Figure C, the MD administration group greatly prolonged the survival period of mice, and the survival rate of the DOX chemotherapy group was lower than that of the PBS+ control group, further indicating that DOX has high toxicity, and the prodrug delivery strategy solves this problem very well. In addition, the synergistic effect of MD-mediated chemotherapy and phototherapy has the highest inhibitory effect on the growth of tumor cells.
[0187] Example 6
[0188] Nanoparticles MD were formed using DSPE-PEG and MB-DOX containing PEG of different molecular weights.
[0189] Then, DLS dynamic light scattering was used to detect the particle size and potential of nanoparticles MD. The results are shown in Table 2.
[0190] Table 2
[0191] <![CDATA[DSPE-PEG 1000 ]]> <![CDATA[DSPE-PEG 2000 ]]> <![CDATA[DSPE-PEG 3400 ]]> <![CDATA[DSPE-PEG 5000 ]]> Particle size (nm) 283.2 101.5 293.9 214 Potential -5.385 -7.508 -3.747 -4.32
[0192] As shown in Table 2, the DSPE-PEG 2000 The particle size of nanoparticles MD assembled with MB-DOX is the smallest, and it is easier to enter the blood.
[0193] In summary, hypochlorous acid-responsive dimer prodrugs and nanoparticles showed efficient therapeutic agent loading capacity and had the best inhibitory effect on tumor cell growth. The results of in vitro tumor killing and in vivo anti-tumor activity showed that the killing rate of nanoparticle MD in vitro can be as high as 90%, and the anti-tumor activity in vivo can significantly prolong the survival period. In addition, it is only concentrated in tumor tissue in vivo and does not diffuse into other tissues, with good targeting. Overall, nanoparticle MD provides an option for combined chemotherapy-phototherapy.
[0194] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A hypochlorous acid-responsive dimer prodrug, It is characterized in that The structural formula is shown below:
2. The method for preparing the dimer prodrug according to claim 1, It is characterized in that The steps include: reacting doxorubicin and the compound represented by formula I in a solvent to obtain the dimer prodrug; 3. The preparation method according to claim 2, It is characterized in that The mass ratio of doxorubicin to the compound represented by formula I is (0.2-1.5):1; and / or, the solvent is selected from one or more of dichloromethane, triethylamine and water; And / or, the reaction further includes post-treatment, wherein the post-treatment includes one or more of extraction, washing and drying; And / or, the reaction temperature is 10 to 30°C; And / or, the reaction time is 10 to 60 hours.
4. The preparation method according to claim 3, It is characterized in that The extraction was carried out using dichloromethane; and / or, washing with a sodium chloride aqueous solution; And / or, drying is performed using anhydrous sodium sulfate.
5. A nanoparticle, It is characterized in that The method comprises the dimer prodrug as claimed in claim 1 and a polymer material.
6. The nanoparticles according to claim 5, It is characterized in that The polymer material is a polymer material containing any one or more block structures of polyethylene glycol, polylactic acid, polyglycolide, poly(lactide-glycolide), polycaprolactone, polytrimethylene carbonate, polydioxanone, polyacrylic acid, polyacrylate and polypolypeptide; and / or, the encapsulation efficiency of the nanoparticles is 80-95%; And / or, the particle size of the nanoparticles is 80 to 120 nm.
7. The method for preparing nanoparticles according to claim 5 or 6, It is characterized in that The steps include: The dimer prodrug and the polymer material are dissolved in an organic solvent to obtain a mixed solution, and the mixed solution is added dropwise to an inorganic solvent. Obtaining the nanoparticles; Preferably, the organic solvent is selected from one or both of ethanol and DMSO; Preferably, the inorganic solvent is selected from one or both of buffer or water.
8. A pharmaceutical composition, It is characterized in that It comprises the dimer prodrug as claimed in claim 1 or the nanoparticles as claimed in any one of claims 5 to 6, and a pharmaceutically acceptable excipient.
9. Use of the dimer prodrug according to claim 1, the nanoparticle according to any one of claims 5 to 6, or the pharmaceutical composition according to claim 8 in the preparation of anti-tumor drugs.
10. The use according to claim 9, It is characterized in that The anti-tumor drug is administered by injection, oral administration or local administration; And / or, the tumor in the anti-tumor drug is selected from one or more of breast cancer, bronchial lung cancer, ovarian cancer, soft tissue sarcoma, osteogenic sarcoma, rhabdomyosarcoma, Ewing sarcoma, blastoma, neuroblastoma, bladder cancer, thyroid cancer, prostate cancer, head and neck squamous cell carcinoma, testicular cancer, gastric cancer and liver cancer.
Citation Information
Cited By
Activated methylene blue bonding medicine as well as preparation method and application thereof
CN119638762A
Active oxygen activated nitrogen mustard prodrug as well as preparation method and application thereof
CN119899157A
Methylene blue-fingolimod prodrug based on hypochlorous acid activation as well as preparation method and application of methylene blue-fingolimod prodrug
CN122079927A
Methylene blue-fingolimod prodrugs activated by hypochlorous acid and methods of making and using the same
CN122079927B
